

**Musculoskeletal Australia
Pharmaceutical Benefits Advisory Committee (PBAC)**



MUSCULOSKELETAL
AUSTRALIA

Musculoskeletal relevant drugs for consideration at the July 2021 PBAC Meeting

Below is a list of the musculoskeletal relevant drugs for consideration by the PBAC at their next meeting in July 2021. Consumer comments about any of these drugs must be received by the PBAC **by 5pm (AEST) on Wednesday 26 May 2021**.

If you wish to submit your comments to PBAC with the help of the MSK staff, please respond to the questions in the last column of the table below via email **by no later than 5pm (AEST) on Wednesday, 19 May 2021**. Please send your email responses to info@msk.org.au

Drug name	Musculoskeletal condition/s (What is the drug used to treat?)	Purpose of the submission (Nature of the request by the sponsor or drug company)	If you wish to make a comment about these requests via MSK, please respond to the following questions
ADALIMUBAB	Severe active juvenile idiopathic arthritis; Severe active rheumatoid arthritis; Severe psoriatic arthritis; Ankylosing spondylitis	Pfizer Australia Pty Ltd is requesting both General Schedule and Section 100 (Highly Specialised Drug Program) listing of the Adalimumab biosimilar under the same conditions as its reference biologic. The brand name is Abrilada®	1) How does having any of the listed conditions here affect your daily life? 2) What are the reasons why your current treatment isn't fully meeting your needs? 3) What do you think would be the benefits (or additional benefits) of having this drug available? 4) Are there any reasons why you think this request should not be approved?

Drug name	Musculoskeletal condition/s (What is the drug used to treat?)	Purpose of the submission (Nature of the request by the sponsor or drug company)	If you wish to make a comment about these requests via MSK, please respond to the following questions
ETANERCEPT	Rheumatoid arthritis; Ankylosing spondylitis; Non-radiographic axial spondyloarthritis; Juvenile idiopathic arthritis	Pfizer Australia Pty Ltd is requesting both General Schedule and Section 100 (Highly Specialised Drugs Program) listings of Etanercept in dose dispenser cartridges under the same conditions as the currently listed pre-filled syringes. The brand name is Enbrel®	1) How does having any of the listed conditions affect your daily life? 2) What are the reasons why your current treatment isn't fully meeting your needs? 3) What do you think would be the benefits (or additional benefits) of having this drug available in dose dispenser cartridges as well as the pre-filled syringes? 4) Are there any reasons why you think this request should not be approved?
HYPROMELLOSE	Severe dry eye syndrome, including Sjogren's syndrome	Petrus Pharmaceuticals Pty Ltd is requesting a restricted benefit listing of a new brand under the same conditions as the currently listed hypromellose eye drops; and to seek advice on therapeutic bioequivalence. The brand name is Revive Tears®	1) How does having severe dry eye syndrome (including Sjogren's syndrome) affect your daily life? 2) What are the reasons why your current treatment isn't fully meeting your needs? 3) Are there any reasons why you think this request should not be approved?

Drug name	Musculoskeletal condition/s (What is the drug used to treat?)	Purpose of the submission (Nature of the request by the sponsor or drug company)	If you wish to make a comment about these requests via MSK, please respond to the following questions
SECUKINUMAB	Ankylosing spondylitis (AS)	Novartis Pharmaceuticals Australia Pty Ltd is requesting an increase in the maximum quantity to 2 with their Injection 150 mg in 1 mL pre-filled pens and a reduction in the number of repeats from 5 to 2. The brand name is Cosentyx®	<p>1) How does having AS affect your daily life?</p> <p>2) What are the reasons why your current treatment isn't fully meeting your needs?</p> <p>3) What do you think would be the advantages or disadvantages of having the quantity increased to 2 pre-filled pens but the number of repeats reduced from 5 to 2?</p> <p>4) Are there any reasons why you think this request should not be approved?</p>